# Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

> **NCT01838876** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 442 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Antidepressant Therapy (ADT)

## Key facts

- **NCT ID:** NCT01838876
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-29
- **Primary completion:** 2015-07-27
- **Final completion:** 2015-07-27
- **Target enrollment:** 442 (ACTUAL)
- **Last updated:** 2019-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838876, "Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01838876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*